<DOC>
	<DOCNO>NCT01036009</DOCNO>
	<brief_summary>There curative therapy acute leukemia patient relapse transplant . Patients develop clinically significant graft versus host disease ( GVHD ) low rate relapse develop GVHD . We initiate study post-transplant fast withdrawal immunosuppression donor lymphocyte infusion , goal achieve full donor chimerism child hematologic malignancy . If hypothesis full donor chimerism result leukemia-free survival correct , use immune modulation achieve full donor chimerism decrease relapse rate thus increase survival . The goal Phase II study identify achieve full donor chimerism whole blood CD3+ leukemia-specific ( CD14/15+ , CD19+ , CD33+ CD34+ ) subset may decrease risk relapse patient undergo allogeneic transplant hematologic malignancy .</brief_summary>
	<brief_title>A Study Withdrawal Immunosuppression Donor Lymphocyte Infusions Following Allogeneic Transplant Pediatric Hematologic Malignancies</brief_title>
	<detailed_description>The goal Phase II study identify achieve full donor chimerism whole blood , CD3+ , leukemia-specific subset ( CD3+ , CD14/15+ , CD19+ , CD33+ CD34+ subset ) may decrease risk relapse patient undergo allogeneic transplant hematologic malignancy . We estimate total 50 recipient patient need enrol . Of 50 recipient patient observation group intervention group form . We want enroll 25 recipient patient intervention group , group receive study intervention outcomes focus statistical analysis study . Intervention involve fast withdrawal immunosuppression follow transplant donor lymphocyte infusion ( DLI ) full donor chimerism achieve . Chimerism genetic test measure proportion donor 's recipient 's cell blood bone marrow . Twenty five patient undergo fast withdrawal immunosuppression 33 -50 % ( 8-13 ) undergo DLI follow fast withdrawal immunosuppression . Patients peripheral blood ( PB ) chimerism test upon engraftment . A confirmatory test PB bone marrow ( BM ) do day 45±7 . Minimal residual disease ( MRD ) examine immunoflow , FISH , cytogenetics PCR . Patients positive MRD faster schedule immune intervention patient negative MRD . Interventions carry 1 year post transplant . If confirmatory testing show evidence MRD full donor chimerism present subset , patient part `` observation '' group observe 2 year post transplant . Chimerism repeat 12 24 month post transplant . If patient mixed chimerism confirmatory test ( PB BM ) , patient part `` intervention '' group fast withdrawal immunosuppression initiate . If patient mixed chimerism one confirmatory test ( PB BM ) , test repeat 2 week patient proceed either observation intervention , base result repeat test . Patients follow incidence acute chronic Graft Versus Host Disease ( GVHD ) relapse 2 year post transplant . The study consider successful relapse rate 2 year post transplant ≤20 % entire study ≤ 40 % intervention group .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Juvenile</mesh_term>
	<mesh_term>Monosomy</mesh_term>
	<criteria>Age 6 month 25 year . Diagnoses acute leukemia ( AML , ALL , biphenotypic leukemia ) , preleukemic syndrome ( monosomy 7 bone marrow clonal malformation ) , JMML , myelodysplastic syndrome CML . Undergoing allogeneic transplant standard care . Performance status : Karnofsky/Lansky &gt; 60 % . Availability pretransplant recipient 's DNA donor 's DNA chimerism test . This could DNA material DNA could extract . Frozen blood would prefer . For patient , post transplant specimen infiltrate donor cell may use . Bone marrow PBMTC stem cell source.HLA matching : donor recipient match minimum 7/8 antigen ( A , B , C DrB1 ) bone marrow PBMTC transplant . No history ≥grade III acute GVHD . Treatment experimental protocol , withdrawal immunosuppression interfere procedure followup primary study . Leukemia relapse define &gt; 5 % blast bone marrow exam &gt; 1 % leukemia cell immunoflow MRD , presence extramedullary leukemia . History acute GVHD ≥ stage III degree active acute cGVHD . On steroid reason . Any condition compromise compliance objective procedure protocol , judge principal investigator . Cells DLI obtain donor .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Hematologic</keyword>
	<keyword>Malignancy</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Pre-leukemic</keyword>
	<keyword>Allogeneic</keyword>
	<keyword>Transplant</keyword>
	<keyword>Pediatric</keyword>
</DOC>